BTK and atrial fibrillation: Although one report suggests that ibrutinib-induced atrial fibrillation may be related to on-target toxicity via inhibition of BTK [24], newer BTK inhibitors such as acalabrutinib have not been associated with increased rates of AF [25], suggesting an off-target mechanism.